We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Immunogenicity Study of H3N2 M2SR Monovalent Influenza Vaccine in Healthy Volunteers

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02822105
First Posted: July 4, 2016
Last Update Posted: August 2, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
FluGen Inc
  Purpose
The purpose is of this study is to assess the safety and tolerability of three dose levels of H3N2 M2SR influenza vaccine versus placebo delivered intranasally to healthy adult subjects.

Condition Intervention Phase
Flu Biological: the H3N2 M2SR monovalent influenza vaccine Other: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Phase 1 Clinical Study To Investigate The Safety And Immunogenicity Of The H3N2 (A/Brisbane/10/2007) M2SR Monovalent Influenza Vaccine

Resource links provided by NLM:


Further study details as provided by FluGen Inc:

Primary Outcome Measures:
  • Frequency and severity of local and systemic adverse events (AEs) through 28 days vaccination and cumulatively through Day 180 [ Time Frame: from baseline through study completion (Day 180) ]
    Record adverse events


Secondary Outcome Measures:
  • Percentage of subjects demonstrating seroconversion to vaccine hemagglutinin antigen and the magnitude of the immune response [ Time Frame: from baseline through study completion (Day 180) ]
    Test antibodies pre and post vaccination

  • Length of time that vaccine virus shedding is detected [ Time Frame: at 24, 48 and 72 hours post-vaccination and on day 7 post vaccination ]
    Test nasal swabs for virus


Enrollment: 96
Actual Study Start Date: June 2016
Estimated Study Completion Date: June 2018
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: H3N2 M2SR monovalent influenza vaccine
This group will receive a low, medium or high dose of the H3N2 M2SR monovalent influenza vaccine administered intranasally. It will be compared with placebo in a 3:1 ratio.
Biological: the H3N2 M2SR monovalent influenza vaccine
The H3N2 Bris10 M2SR influenza vaccine candidate (Bris10 M2SR) is formulated to contain different levels of an M2-deleted non-replicating influenza virus expressing the HA and NA genes of influenza strain A/Brisbane/10/2007.
Experimental: placebo
This group will receive saline administered intranasally.
Other: Placebo
saline

Detailed Description:

Healthy adult subjects will be screened with the objective to randomize 96 subjects with the lowest levels of H3 hemagglutination inhibition (HAI) titers that meet all inclusion/exclusion criteria and have signed an informed consent. Subjects will be rank ordered from low to high based on their HAI titer. Subjects will then be assigned treatment based on a randomization to either active vaccine or placebo. The first two subjects dosed in each dose cohort will serve as sentinels and will receive active IP (not randomized).

Subjects will receive a single dose inoculation of the H3N2 M2SR seasonal monovalent influenza vaccine administered intranasally as a liquid formulation, or placebo (saline). The sentinel subjects will be vaccinated in dose cohort 1 and a safety monitoring committee (SMC) will conduct a review of safety data, tolerability, reactogenicity, and clearance of infectious virus prior to dosing the remaining subjects of the cohort with active or placebo.

After the last subject in the cohort has been followed for at least 7 days the SMC will conduct another review of safety data prior to proceeding to the next higher dose level: Cohort 2. The same processes of sentinel subject dosing and SMC review will be conducted for Cohorts 2 and 3.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 49 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Key Inclusion Criteria:

  • Individuals who are in good health at the time of entry into the study as determined by medical history, physical examination, vital signs, and clinical safety laboratory values and clinical judgement of the Principal Investigator (PI)
  • The subject signs and dates a written, informed consent form and any required privacy authorization
  • Willing to use a reliable form of contraception approved by the Investigator (e.g., intrauterine device [IUD], female condom, diaphragm with spermicide, cervical cap, use of condom by the sexual partner or a sterile sexual partner) for 1 month prior to vaccination and until 28 days following the last visit
  • Individuals who are willing and able to communicate with the Investigator and understand the requirements of the study
  • Individuals who can comply with trial procedures and are available for the duration of follow-up

Key Exclusion Criteria:

  • Any subject with the following screening lab values (per the Food and Drug Association (FDA) Guidance: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials):

    1. Any ≥ Grade 2 abnormality
    2. Clinically significant Grade 1 abnormality as judged by the Principal Investigator or
    3. Clinically non-significant Grade 1 abnormality as judged by the Principal Investigator which, upon repeat testing becomes more abnormal
  • History or clinical manifestation of clinically significant health conditions including but not limited to: mental illness, active hematological, renal, hepatic, pulmonary, central nervous, neurological, cardiovascular, endocrine (including diabetes mellitus) or gastrointestinal disorders
  • Acute febrile illness within 72 hours prior to vaccination, defined as the presence of a moderate or severe illness with or without fever (as determined by the Investigator through medical history and physical examination), or presence of a fever >38ºC orally.
  • Any confirmed or suspected immunosuppressive or immunodeficient state including: asplenia, recurrent severe infections and chronic (more than 14 days) immunosuppressant medication
  • Living in the same household with any person with a non-functional or suppressed immune system
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02822105


Locations
United States, Kansas
JCCT
Lenexa, Kansas, United States, 66219
Sponsors and Collaborators
FluGen Inc
Investigators
Study Director: Renee Herber FluGen Inc
Principal Investigator: Carlos Fierro, MD Johnson County Clin Trials
  More Information

Responsible Party: FluGen Inc
ClinicalTrials.gov Identifier: NCT02822105     History of Changes
Other Study ID Numbers: H3N2-V001
First Submitted: June 27, 2016
First Posted: July 4, 2016
Last Update Posted: August 2, 2017
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Publications and post to site

Additional relevant MeSH terms:
Vaccines
Immunologic Factors
Physiological Effects of Drugs